Hemodynamic

WASHINGTON — The 5-year rate of structural valve deterioration was lower in self-expanding valves for transcatheter aortic valve replacement than in surgical valves, researchers reported.

Abbott announced its sensor providing hemodynamic-guided management of patients with HF has received an expanded indication from the FDA.

Philips announced the FDA clearance and launch of a new version of its point-of-care hand-held ultrasound for CV and other applications.

Device therapy for pulmonary artery-pressure-guided management of patients with HF was beneficial regardless of ejection fraction, according to new data from the GUIDE-HF trial presented at TCT 2021.

Management of patients with HF with or without pulmonary artery pressure information derived from an implantable device (CardioMEMS, Abbott).

The GUIDE-HF trial of hemodynamic-guided management of HF did not meet its primary endpoint, but analyses limited to the period before the COVID-19 pandemic showed benefit in a broader range of patients than previously demonstrated.

Despite significant improvements in care, HF remains a progressive, complex disease process associated with significant hospital admissions and cost.

For this issue, Cardiology Today spoke with Editorial Board Member Jeffrey S. Berger, MD, associate professor of medicine and surgery with appointments in cardiology, hematology and vascular surgery at NYU Grossman School of Medicine and director of the Center for the Prevention of Cardiovascular Disease at NYU Langone Health.

A protocol involving early use of invasive hemodynamics and mechanical circulatory support conferred a survival benefit in patients with acute MI and cardiogenic shock, a speaker reported.